ClinicalTrials.gg
RecruitingNCT07067112SIIM-regUpdated Oct 14, 2026

Suppressive Functions of Regulatory T Cells in Migraine

An interventional study of Blood sampling, questionnaire and phone call in Chronic Migraine, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 14, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Migraine Disorders with a site in France — 14 open to participants now, 20 under way, 6 of them phase 3. Migraine Disorders · France.

Planned enrollment
51st of 51
24 · median 450
Started
2026
with 4 others
No phase
14 of 71
5 open now
Primary completion
2027-11
later than 10 of 19 live
Registered
66th of 71
by date
Lead sponsor
9 of 71
University Hospital, Clermont-Ferrand

Among the 71 studies in Migraine Disorders with a site in France, this one is the 51st largest by planned enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2026, is one of 14 with no phase, reaches primary completion later than 10 of the 19 other live ones, and was the 66th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

14 of the 71 studies in Migraine Disorders with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Migraine Disorders with a site in France, or all of them as a file.
02

Study summary

Migraine is a frequent, disabling condition, of great social and economical impact worldwide. This condition is more frequent in women and subjects with autoimmune and/or inflammatory diseases. Cytokine and immune cell dysregulations have been evidenced in migraine. Inflammation seems to play an important role in migraine chronification; however, the inflammatory mechanisms involved in migraine pathophysiology remain unclear. Regulatory T (Treg) cells play a central role in maintaining immune homeostasis. They regulate effector T (Teff) cell proliferation and cytokine production, through several suppressive mechanisms, such as the hydrolysis of adenosine triphosphate (ATP) into adenosine (ADO), mediated by surface enzymes Cluster Differentiation 39 (CD39) and Cluster Differentiation 73 (CD73). ATP is involved in pain processes in migraine, and insufficient hydrolysis could participate in pain chronification. Recent studies suggest altered proportions of Treg cells in migraine, and decreased levels of CD39-positive (CD39+) Treg cells, suggesting Treg suppressive functions may be decreased in the disease. However, there have been no functional studies to date to confirm this hypothesis.

The investigators believe Treg suppressive functions may be decreased in migraine, and that such alterations may be caused by a malfunction in the ADO pathway.

Read the detailed description

Migraine is a major and global public health concern that affects 14% of the population worldwide. It is 2 to 3 times more prevalent in women than men and is the second leading cause of disability. Many patients remain unresponsive to currently available treatments. As evidenced in different studies, including our own, several auto-immune and inflammatory disorders, such as multiple sclerosis, are associated with a higher prevalence of migraine and a higher risk for migraine chronification (at least 15 headache days per month) compared to the general population. These findings suggest that inflammation may play an important role in migraine chronification. Cytokine and immune cell dysregulations have been evidenced in the disease but the role of inflammation in migraine pathophysiology remains unclear. Among T lymphocytes, regulatory T (Treg) cells play an important role in maintaining immune homeostasis. They regulate pro-inflammatory effector T (Teff) cells and proinflammatory cytokine release (IL-6, IL-17, interferon-γ) through different suppressive mechanisms such as the hydrolysis of pro-inflammatory and nociceptive adenosine triphosphate (ATP) into anti-inflammatory and antinociceptive adenosine (ADO), by Treg surface enzymes CD39 and CD73, present on 40% and 6-10% of Treg cells, respectively. ADO then suppresses Teff cells by binding to their ADO receptor A2A. ATP is involved in the transduction of pain signals in migraine and its insufficient hydrolysis can lead to pain chronification. It has been evidenced that Tregs naturally suppress interferon (IFN)-γ production by Teff cells. Their CD39-positive (CD39+) subsets also suppress IL-17 production by Teff cells, whereas CD39-negative (CD39-) Tregs seem to increase IL-17 secretion. Recent studies have shown altered Treg proportions in migraine compared to controls and Treg subpopulation dysregulations, such as decreased CD39+Treg cell levels. This further suggests that Treg suppressive functions may be altered in migraine, but no functional assays have been led to confirm that.

In this study, the investigators aim to determine whether Treg cells play a role in migraine pathophysiology, by answering the following 3 separate questions: Question 1) Are Treg suppressive functions decreased in migraine patients? Question 2) Are CD39+Treg cells functionally deficient in migraine patients? Question 3) Is the hydrolytic activity of enzyme CD39 reduced in migraine patients?

Through Treg/Teff coculture the investigators will assess the ability of total Treg and CD39+Treg cells to inhibit Teff proliferation and pro-inflammatory cytokine secretion and measure the hydrolytic activity of Treg enzyme CD39 on ATP in chronic migraine patients versus healthy controls. The use of human immune cells (Treg and Teff lymphocytes) in our experiments will allow the investigators to better understand migraine pathophysiology, with a direct application to human subjects, as well as to avoid animal testing and suffering. Through its animal-free setting, following the 'Reduce, Refine, Replace (3Rs)' principle, the investigators wish to promote animal-free research and the reduction of animal use for reagent production by using recombinant antibodies for flow cytometry and synthetic medium supplements for cell culture. This study will lead to a better understanding of the role of inflammation and Treg cells in migraine pathophysiology and will provide new perspectives for the development of personalized treatments according to the immune pain profile of migraine patients.

The investigators aim to show that Treg suppressive functions are altered in migraine and that the ADO pathway is deficient. Through Treg/Teff coculture the investigators will measure the ability of Tregs to inhibit Teff proliferation and cytokine secretion and assess the CD39-related hydrolytic activity of Tregs. This will allow the investigators to study Treg cells suppressive functions on Teff cells in female patients with chronic migraine and healthy female control participants.

03

Conditions studied

  • Chronic Migraine

Keywords

  • Migraine
  • Inflammation
  • Immune system
  • Regulatory T cells
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females
  • 18 to 50 years old
  • For chronic migrain : At least 8 monthly migraine days

Exclusion criteria

Exclusion Criteria:

  • \< or = 17kg/m² or > or = 30kg/m²
  • Diagnosis or suspicion of type 2 diabetes, auto-immune or inflammatory diseases, immunodeficiency diseases
  • Diagnosis of headache of non-migraine origin, except for tension type headache (i.e.: cluster headache, post-traumatic headache, cerebral tumour…)
  • For controls participants : tension type headache with 4 or more monthly headache days
  • Pregnancy, delivery, miscarriage, breastfeeding, participation in a medically assisted human reproduction program (ovary stimulation/hormone therapy) \< 3 months before blood sampling
  • Menopause, hysterectomy, or bilateral oophorectomy
  • Modification of prophylactic anti-migraine therapy (start, change of molecule, interruption) \< 1 month before blood sampling (for migraine participants)
  • Hormone therapy (beside and treatment of endometriosis)
  • Transplantation (solid organ or bone marrow)
  • Cancer (active or remitting) \< 1 year before blood sampling (solid organ or blood)
  • Haematologic disease (benign or malignant) of the lymphoid lineage
  • Guardianship, curatorship, safeguard of justice or deprivation of liberty
  • For controls : history of migraine
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Chronic migraine

    Chronic migraine patients will donate 100 milliliters (mL) of peripheral and venous blood, answer a questionnaire and 2 phone calls (one at day 1 and the other at day 3 from the blood test).

    Biological: Blood sampling, questionnaire and phone call

  • Experimental
    Controls

    Non-migraine controls will donate 100 mL of peripheral and venous blood, answer a questionnaire and 2 phone calls (one at day 1 and the other at day 3 from the blood test).

    Biological: Blood sampling, questionnaire and phone call

Interventions

  • BiologicalBlood sampling, questionnaire and phone call

    The blood sample will drawn outside of a migraine attack (no migraine within 6 hours prior to the blood test), and the questionnaire will be auto-administered

06

What researchers measure

Primary outcomes

  1. Treg cell suppressive functions

    To measure the suppressive effect of Treg cells on Teff cells in chronic migraine patients and healthy controls

    Time frame: Day 0

Secondary outcomes

  1. CD39+ Treg cell suppressive functions

    To measure the suppressive effect of CD39+Treg cells on Teff cells in chronic migraine patients and healthy controls

    Time frame: Day 0

  2. CD39 activity

    To measure the hydrolytic activity of Treg enzyme CD39 in chronic migraine patients and healthy controls

    Time frame: Day 0

  3. Cytokines

    To measure the levels of cytokine levels in blood : interleukin (IL)-6, IL-10, IL-17, IFN-g and transforming growth factor b

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022 Apr 12;23(1):34. doi: 10.1186/s10194-022-01402-2. PubMed 35410119 ↗
  • Ashina M. Migraine. N Engl J Med. 2020 Nov 5;383(19):1866-1876. doi: 10.1056/NEJMra1915327. No abstract available. PubMed 33211930 ↗
  • Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, Bonassi S; Italian Migraine Registry study group. Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study. Neurology. 2023 Sep 12;101(11):482-488. doi: 10.1212/WNL.0000000000207292. Epub 2023 Apr 18. PubMed 37072224 ↗
  • Moisset X, Giraud P, Dallel R. Migraine in multiple sclerosis and other chronic inflammatory diseases. Rev Neurol (Paris). 2021 Sep;177(7):816-820. doi: 10.1016/j.neurol.2021.07.005. Epub 2021 Jul 27. PubMed 34325914 ↗
  • Moisset X, Ouchchane L, Guy N, Bayle DJ, Dallel R, Clavelou P. Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. Pain. 2013 Dec;154(12):2691-2699. doi: 10.1016/j.pain.2013.07.050. Epub 2013 Aug 2. PubMed 23911697 ↗
  • Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019 Aug;15(8):483-490. doi: 10.1038/s41582-019-0216-y. Epub 2019 Jul 1. PubMed 31263254 ↗
  • Thuraiaiyah J, Erritzoe-Jervild M, Al-Khazali HM, Schytz HW, Younis S. The role of cytokines in migraine: A systematic review. Cephalalgia. 2022 Dec;42(14):1565-1588. doi: 10.1177/03331024221118924. Epub 2022 Aug 12. PubMed 35962530 ↗
  • Nurkhametova D, Kudryavtsev I, Khayrutdinova O, Serebryakova M, Altunbaev R, Malm T, Giniatullin R. Purinergic Profiling of Regulatory T-cells in Patients With Episodic Migraine. Front Cell Neurosci. 2018 Sep 25;12:326. doi: 10.3389/fncel.2018.00326. eCollection 2018. PubMed 30319363 ↗
  • Loza MJ, Anderson AS, O'Rourke KS, Wood J, Khan IU. T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus. Cell Immunol. 2011;271(1):110-7. doi: 10.1016/j.cellimm.2011.06.010. Epub 2011 Jul 18. PubMed 21763644 ↗
  • Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008 Jul;8(7):523-32. doi: 10.1038/nri2343. PubMed 18566595 ↗
  • Giniatullin R, Nistri A, Fabbretti E. Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF. Mol Neurobiol. 2008 Feb;37(1):83-90. doi: 10.1007/s12035-008-8020-5. Epub 2008 May 6. PubMed 18459072 ↗
  • Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O'Farrelly C, Tubridy N, Mills KH. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol. 2009 Dec 1;183(11):7602-10. doi: 10.4049/jimmunol.0901881. Epub 2009 Nov 16. PubMed 19917691 ↗
  • Faraji F, Shojapour M, Farahani I, Ganji A, Mosayebi G. Reduced regulatory T lymphocytes in migraine patients. Neurol Res. 2021 Aug;43(8):677-682. doi: 10.1080/01616412.2021.1915077. Epub 2021 Apr 14. PubMed 33853506 ↗
  • Arumugam M, Parthasarathy V. Reduction of CD4(+)CD25(+) regulatory T-cells in migraine: Is migraine an autoimmune disorder? J Neuroimmunol. 2016 Jan 15;290:54-9. doi: 10.1016/j.jneuroim.2015.11.015. Epub 2015 Nov 28. PubMed 26711570 ↗
  • Yang L, Zhou Y, Zhang L, Wang Y, Zhang Y, Xiao Z. Aryl hydrocarbon receptors improve migraine-like pain behaviors in rats through the regulation of regulatory T cell/T-helper 17 cell-related homeostasis. Headache. 2023 Sep;63(8):1045-1060. doi: 10.1111/head.14599. Epub 2023 Aug 4. PubMed 37539825 ↗
  • Anaya JM. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev. 2012 Sep;11(11):781-4. doi: 10.1016/j.autrev.2012.02.002. Epub 2012 Feb 12. PubMed 22353402 ↗
  • Guo Z, Zhang J, Liu X, Unsinger J, Hotchkiss RS, Cao YQ. Low-dose interleukin-2 reverses chronic migraine-related sensitizations through peripheral interleukin-10 and transforming growth factor beta-1 signaling. Neurobiol Pain. 2022 Jun 13;12:100096. doi: 10.1016/j.ynpai.2022.100096. eCollection 2022 Aug-Dec. PubMed 35733705 ↗
  • Okimura H, Tanaka Y, Fujii M, Shimura K, Maeda E, Ito F, Khan KN, Nakamura Y, Mori T, Kitawaki J. Changes in the proportion of regulatory T cell subpopulations during menstrual cycle and early pregnancy. Am J Reprod Immunol. 2022 Dec;88(6):e13636. doi: 10.1111/aji.13636. Epub 2022 Oct 21. PubMed 36217280 ↗
  • Douge A, Vituret C, Carraro V, Parry L, Coudy-Gandilhon C, Lemal R, Combaret L, Maurin AC, Averous J, Jousse C, Bay JO, Verrelle P, Fafournoux P, Bruhat A, Rouzaire P. Temporal regulation of transgene expression controlled by amino acid availability in human T cells. HLA. 2024 Jan;103(1):e15252. doi: 10.1111/tan.15252. Epub 2023 Oct 17. PubMed 37848366 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Nov 2027, 14 months after the start.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 14 months is below that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Jul 16, 2025
StartActual
Sep 10, 2026was Jul 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 14, 2026
Sites
CHU Clermont-Ferrand is now Recruiting
Oct 14, 2026
Start date
Jul 1, 2026→Sep 10, 2026 (actual)
Oct 14, 2026
Eligibility
1 inclusion criterion added, 1 removed; 4 exclusion criteria edited, 1 added, 2 removed
What changed in the criteria
Inclusion criteria
  • RemovedChronic migraine participants : chronic migraine (at least 15 days of headache/month, according to the International Classification of Headache Disorders, 3rd edition criteria
  • AddedFor chronic migrain : At least 8 monthly migraine days
Exclusion criteria
  • EditedDiagnosis of headache of non-migraine origin, except for tension type headache < or = 4 days per month (i.e.: cluster headache, post-traumatic headache, cerebral tumour…)
  • AddedFor controls participants : tension type headache with 4 or more monthly headache days
  • RemovedFlare of the autoimmune/inflammatory disease of interest < 1 month before blood sampling
  • RemovedModification of maintenance therapy for the autoimmune/inflammatory disease of interest (start, change of molecule, interruption) < 3 months before blood sampling
  • EditedModification of prophylactic anti-migraine therapy (start, change of molecule, interruption) < 3 months1 month before blood sampling (for migraine participants)
  • EditedHormone therapy (besidesbeside contraception and treatment of endometriosis)
  • EditedFor controls : diagnosishistory of migraine
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Not yet recruiting→Recruiting
    CHU Clermont-Ferrand is now Recruiting
    Start date Jul 1, 2026→Sep 10, 2026 (now actual)
    Eligibility 1 inclusion criterion added, 1 removed; 4 exclusion criteria edited, 1 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedChronic migraine participants : chronic migraine (at least 15 days of headache/month, according to the International Classification of Headache Disorders, 3rd edition criteria
    • AddedFor chronic migrain : At least 8 monthly migraine days
    Exclusion criteria
    • EditedDiagnosis of headache of non-migraine origin, except for tension type headache < or = 4 days per month (i.e.: cluster headache, post-traumatic headache, cerebral tumour…)
    • AddedFor controls participants : tension type headache with 4 or more monthly headache days
    • RemovedFlare of the autoimmune/inflammatory disease of interest < 1 month before blood sampling
    • RemovedModification of maintenance therapy for the autoimmune/inflammatory disease of interest (start, change of molecule, interruption) < 3 months before blood sampling
    • EditedModification of prophylactic anti-migraine therapy (start, change of molecule, interruption) < 3 months1 month before blood sampling (for migraine participants)
    • EditedHormone therapy (besidesbeside contraception and treatment of endometriosis)
    • EditedFor controls : diagnosishistory of migraine
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07067112
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Sep 10, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
334.73.754.963
Xavier MOISSET
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion